not available for commercial use in U.S.), dulaglutide (Trulicity, Eli Lilly), oral semaglutide (Rybelsus, Novo Nordisk) and efpeglenatide (Sanofi) researchers also found that human and exendin-based GLP-1 receptor agonists reduce risk for all-cause mortality, hospitalization for heart failure, and a composite kidney outcome of development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate or increase in creatinine, renal replacement therapy or renal death
Phase 3 TRIUMPH trial dose schedule updates The phase 3 TRIUMPH program expanded on the phase 2 dosing framework, and the recent results add important context to how dose schedules may evolve
These chemicals have no pedigree, but supplement and peptide vendors sell them, sometimes labeled for "research use only," and they are being acquired by both licensed and unlicensed compounders
Shorter faster treatment option
GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder
